A new UK safety alert asks health services to complete switches from Levemir insulin by 30 November 2026, ahead of supplies being expected to run out by the end of December. The change needs a planned review with the prescribing team, not a patient-led insulin swap.
If Levemir is part of your treatment, the important message is to arrange the transition while supplies remain available. NHS patient information advises people to keep using their prescribed Levemir until their diabetes team explains the replacement plan. This article concerns the UK timetable; arrangements elsewhere may differ.
What has changed?
The Department of Health and Social Care issued National Patient Safety Alert NatPSA/2026/006/DHSC on 1 October. It covers Levemir FlexPen pre-filled pens and Levemir Penfill cartridges, both containing insulin detemir at 100 units/ml. The alert reinforces earlier supply notices rather than announcing a new insulin treatment.
Levemir’s withdrawal was already known. What matters now is the clearer instruction to organisations prescribing and dispensing it: organise switches for existing patients as soon as possible, and no later than 30 November. The alert also says that clinicians should not start new patients on Levemir.
The two dates have different meanings. November is the deadline for the clinical transition. The end of December is when the affected products are being discontinued and stocks are anticipated to be exhausted. Waiting until the supply deadline leaves less room to arrange a review, a prescription and any necessary device training.
Is this a recall because Levemir is unsafe?
No. NHS West Yorkshire’s patient guidance describes the withdrawal as a business decision and states that it is not due to safety concerns with Levemir itself. The safety issue is making sure people who depend on insulin have an appropriate replacement and understand how to use it before supplies end.
The words “patient safety alert” can sound alarming, but they do not mean that everyone should immediately discard the insulin they have. Continuing the prescribed treatment while arranging professional advice is different from ignoring the withdrawal. Stockpiling is not a solution either: Diabetes UK warns that it can make supplies harder for others to obtain and does not remove the need to change insulin eventually.
Who needs to pay attention?
This affects people currently using Levemir, regardless of their type of diabetes. Diabetes UK also highlights people who keep it as a backup insulin, including some insulin-pump users. A medicine that is rarely used may still need to be discussed when a backup plan is reviewed.
Levemir is a long-acting, or basal, insulin. Basal insulin provides background insulin coverage. Some people use it alongside mealtime insulin; others have different combinations of diabetes treatment. The alert is not a direction to change every insulin in a person’s regimen.
If someone helps with your medicines, involve them in the discussion. The NHS guidance allows for reviews through a specialist diabetes team or a GP practice, depending on who manages the person’s care.
What will the replacement review involve?
There is no single replacement that suits everyone. Diabetes UK explains that the choice depends on individual circumstances. The national alert also asks prescribing teams to check current alternative-insulin supply information, because availability can change.
The review is about more than the name on a prescription. The team needs to explain the replacement insulin, the prescribed dose and any new pen or cartridge system. The alert specifically asks clinicians to consider eyesight, hand movements and whether the person or their carer needs additional help administering insulin.
A familiar-looking device is not a reason to assume that its instructions are identical. Ask to be shown how the new equipment works and how to recognise the exact product prescribed. The alert notes that some alternatives come in different strengths, making accurate product selection important.
Useful questions to take to your appointment
- When will my Levemir review take place, and who will organise it?
- What is the exact name of my replacement insulin?
- Will I need a different pen, cartridge or other equipment?
- Can someone show me how to use the new device?
- What glucose-monitoring plan should I follow during the change?
- Who should I contact if I cannot obtain a prescription or have concerns afterwards?
Recent glucose readings can help the discussion. NHS West Yorkshire suggests bringing monitoring information to the review, along with notes about changes such as illness, meals or exercise. Follow the monitoring instructions already agreed with your team; this article does not set a new testing frequency.
Why follow-up matters
The national alert says that closer glucose monitoring is needed initially after an insulin switch and that the prescribing team may need to adjust the dose. It does not provide a universal patient-led conversion rule. Do not copy another person’s replacement dose or work one out from an online discussion.
Before leaving the review, make sure the written plan is understandable and that you know how to get help. If you are worried about running short before the appointment, contact the prescribing service or pharmacist promptly. The alert asks community pharmacists to ensure that a patient has sufficient insulin before referring them back to the prescriber about the switch.
Frequently asked questions
Should I stop using the Levemir I already have?
NHS advice is to keep using it as prescribed until your diabetes team advises you about the change. Do not stop insulin simply because you have read about the withdrawal.
Does the UK deadline apply in every country?
No. The manufacturer is withdrawing Levemir globally, but the dates and service instructions described here come from the UK alert. People outside the UK should check local arrangements with their own care team.
Can I choose a replacement myself?
The replacement and transition plan need to be agreed with the prescribing team. Product availability, equipment and individual needs all matter.
The bottom line
The October alert is a prompt to organise a supported change before supplies end. Keep the focus on an appointment, a clear prescription, device training and follow-up rather than an unsupervised switch.
Related Living Diabetes guides
Sources
- DHSC National Patient Safety Alert, issued 1 October 2026 and full alert.
- Diabetes UK: Levemir withdrawal, updated 5 October 2026.
- NHS West Yorkshire: medicines information and Levemir withdrawal guidance.
General information, not an individual treatment plan. Insulin changes should be agreed with your prescribing team.